Sourcing Guide Contents
Industrial Clusters: Where to Source Pharmaceutical Trade Supplier
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Deep-Dive Market Analysis – Sourcing Pharmaceutical Trade Suppliers from China
Executive Summary
China has solidified its position as a global leader in pharmaceutical manufacturing and supply, offering a highly diversified and scalable ecosystem for sourcing active pharmaceutical ingredients (APIs), finished dosage forms, generics, and contract development and manufacturing services (CDMO). As global demand for cost-effective, quality-assured pharmaceutical products continues to rise, China’s established industrial clusters provide strategic sourcing opportunities—especially for procurement managers seeking reliable trade suppliers with regulatory compliance and export proficiency.
This report identifies the key pharmaceutical industrial clusters in China, evaluates regional strengths, and provides a comparative analysis of leading provinces—Guangdong, Zhejiang, Jiangsu, Shandong, and Shanghai—based on price competitiveness, quality standards, and lead time efficiency.
Key Pharmaceutical Industrial Clusters in China
China’s pharmaceutical manufacturing is concentrated in several coastal and eastern provinces, where infrastructure, regulatory alignment, and supply chain integration are most advanced. The following regions are recognized as primary hubs for pharmaceutical trade suppliers:
| Province/City | Key Industrial Clusters | Specialization | Notable Features |
|---|---|---|---|
| Guangdong | Guangzhou, Shenzhen, Foshan | APIs, OTC drugs, biologics, medical devices | Proximity to Hong Kong; strong export channels; high regulatory compliance with USFDA and EU-GMP |
| Zhejiang | Hangzhou, Ningbo, Shaoxing | APIs, generics, herbal medicines | High concentration of private pharmaceutical firms; strong R&D investment; cost-efficient production |
| Jiangsu | Suzhou, Nanjing, Wuxi, Changzhou | CDMO, biopharmaceuticals, sterile injectables | Home to many multinational partnerships; advanced GMP facilities; strong technical workforce |
| Shandong | Qingdao, Jinan, Weifang | APIs, antibiotics, chemical intermediates | Large-scale chemical industry integration; competitive pricing; evolving quality standards |
| Shanghai | Zhangjiang Hi-Tech Park | Biologics, innovative drugs, CRO/CDMO | Regulatory leadership; proximity to international pharma R&D high-end manufacturing |
Comparative Analysis of Key Pharmaceutical Sourcing Regions
The table below compares the five leading provinces in China based on three critical procurement criteria: Price, Quality, and Lead Time. Ratings are on a scale of 1–5 (5 = highest).
| Region | Price Competitiveness | Quality & Compliance | Lead Time Efficiency | Key Advantages | Procurement Considerations |
|---|---|---|---|---|---|
| Guangdong | 4 | 5 | 5 | USFDA/EU-GMP certified suppliers; excellent logistics via Shenzhen/Hong Kong ports; strong English-speaking trade suppliers | Slightly higher pricing due to premium compliance; ideal for regulated markets |
| Zhejiang | 5 | 4 | 4 | Cost-effective generics and APIs; agile manufacturers; high export volume | Quality varies; due diligence required on smaller suppliers |
| Jiangsu | 4 | 5 | 4 | High-tech CDMO capabilities; strong track record with Western pharma; advanced sterilization tech | Lead times can extend for complex formulations; premium pricing for biologics |
| Shandong | 5 | 3 | 4 | Lowest-cost APIs and bulk chemicals; integrated supply chains | Quality consistency can be inconsistent; more suitable for non-critical or emerging markets |
| Shanghai | 3 | 5 | 4 | Innovation hub; ideal for biologics and clinical trial materials; strong IP protection | Highest pricing; best suited for high-margin or niche products |
Sourcing Strategy Recommendations
-
For Regulated Markets (US, EU, Japan):
Prioritize Guangdong and Jiangsu for suppliers with USFDA, EU-GMP, or PIC/S certifications. These regions offer the highest compliance levels and audit readiness. -
For Cost-Sensitive Procurement (Emerging Markets, OTC):
Zhejiang and Shandong offer compelling value. Conduct rigorous supplier qualification, including on-site audits and batch testing. -
For Biologics and Advanced Therapeutics:
Focus on Shanghai and Suzhou (Jiangsu) for CDMO partners with experience in monoclonal antibodies, vaccines, and cell & gene therapies. -
Logistics & Lead Time Optimization:
Leverage Guangdong’s proximity to Hong Kong and Shenzhen ports for faster export processing. Use bonded logistics zones to reduce customs delays.
Risk Mitigation & Compliance Guidance
- Verify Regulatory Status: Use NMPA (China’s National Medical Products Administration) databases and third-party audit platforms (e.g., NSF, SGS, TÜV) to confirm facility certifications.
- IP Protection: Execute robust confidentiality agreements and work with suppliers registered under China’s Patent Law and international treaties (e.g., PCT).
- Supply Chain Transparency: Require full traceability of raw materials (especially from Tier 2–3 suppliers) to comply with FDA’s Drug Supply Chain Security Act (DSCSA) and EU Falsified Medicines Directive (FMD).
Conclusion
China remains a pivotal source for pharmaceutical trade suppliers, with distinct regional advantages across cost, quality, and lead time. Guangdong and Jiangsu lead in quality and compliance, making them ideal for regulated markets, while Zhejiang and Shandong offer cost leadership for volume-driven procurement. Shanghai stands out for innovation and high-end manufacturing.
Procurement managers should adopt a tiered sourcing strategy, aligning supplier selection with market requirements, regulatory obligations, and product complexity. With proper due diligence, China’s pharmaceutical clusters offer scalable, reliable, and competitive sourcing opportunities in 2026 and beyond.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Q2 2026 | Confidential – For B2B Procurement Use Only
Technical Specs & Compliance Guide
SourcifyChina B2B Sourcing Report: Pharmaceutical Trade Suppliers
Prepared for Global Procurement Managers | Q1 2026
Executive Summary
This report outlines critical technical specifications, compliance requirements, and quality control protocols for sourcing pharmaceutical trade suppliers in 2026. With global regulatory scrutiny intensifying (e.g., FDA’s Pharmaceutical Quality for the 21st Century initiative and EU MDR/IVDR alignment), adherence to precise tolerances, material standards, and certifications is non-negotiable. Suppliers failing to meet these parameters risk supply chain disruption, regulatory penalties, and product recalls. SourcifyChina recommends rigorous pre-qualification audits and real-time compliance tracking.
I. Technical Specifications: Key Quality Parameters
A. Material Requirements
| Component | Acceptable Materials | Critical Tolerances | Testing Standard |
|---|---|---|---|
| Primary Packaging | Type I Borosilicate Glass (USP <660>), Cyclic Olefin Copolymer (COC) | Glass: Hydrolytic Class 1 (≤0.1mL 0.02N HCl); COC: ≤5ppm leachables | USP <1790>, ISO 11337 |
| Secondary Packaging | Pharmaceutical-grade cardboard (FSC-certified), Alu-Alu foil | Foil: Thickness 0.025±0.002mm; Seal Strength: 0.8–1.2 N/15mm | ISO 15378, ASTM F88 |
| Active Ingredients | USP/NF, EP, or JP-compliant APIs | Purity: ≥99.0% (HPLC); Residual Solvents: ICH Q3C Class 2 limits | ICH Q6A, USP <467> |
B. Manufacturing Tolerances
- Dimensional Accuracy: ±0.05mm for vial neck finish (ISO 8362-1:2023)
- Sterility Assurance Level (SAL): 10⁻⁶ (ISO 11135:2023)
- Particulate Matter: ≤6,000 particles/mL (>10µm) per USP <788>
- Endotoxin Limits: ≤0.25 EU/mL (LAL test, USP <85>)
Procurement Action: Require suppliers to provide material traceability logs (batch-specific CoA) and in-process validation reports for all critical dimensions.
II. Essential Certifications & Compliance Requirements
Non-negotiable for market access. Validity must be verified via official databases (e.g., FDA OGD, EUDAMED).
| Certification | Scope | 2026 Regulatory Update | Verification Method |
|---|---|---|---|
| FDA 21 CFR Part 211 (cGMP) | US market entry for drugs/devices | Enhanced data integrity requirements (ALCOA+ 2.0) | FDA Establishment Inspection Report |
| EU GMP Annex 1 | Sterile manufacturing (EMA) | Stricter environmental monitoring (Grade A: ≤5 CFU/m³) | EMA EudraGMP Certificate |
| ISO 13485:2026 | Quality management for medical devices | Cybersecurity annex for connected devices | IAF CertSearch Database |
| PIC/S GMP | Global harmonization (70+ countries) | Mandatory serialization for all Rx drugs (2026 deadline) | PIC/S PE 009-17 Rev. 2 Audit Report |
| WHO GMP | Emerging markets (Africa, SE Asia) | New temperature mapping protocols for cold chain | WHO Certificate of GMP Compliance |
Critical Note: UL certification is irrelevant for pharmaceuticals (applies to electrical safety). Prioritize ISO 11137 (sterilization) over UL.
III. Common Quality Defects & Prevention Strategies
| Common Quality Defect | Root Cause | Prevention Protocol | Procurement Verification Step |
|---|---|---|---|
| Container Closure Integrity Failure | Poor sealing, material deformation | • 100% HVLD (High-Voltage Leak Detection) testing • ISO 15378:2023-compliant blister sealing |
Review HVLD validation report; audit seal force logs |
| Particulate Contamination | Poor cleanroom practices, equipment wear | • ISO 14644-1 Class 5 environment • In-line particle counters (real-time monitoring) |
Verify cleanroom certification; request particle logs |
| Endotoxin Excursion | Water system failure, inadequate depyrogenation | • WFI (Water for Injection) per USP <1231> • Dry-heat depyrogenation (250°C, 30+ min) |
Audit WFI validation; check depyrogenation cycle logs |
| Labeling/Serialization Errors | Software misconfiguration, human error | • 100% automated vision inspection • GS1 standards compliance (2026 global mandate) |
Inspect serialization test records; validate GS1 barcodes |
| API Degradation | Improper storage, humidity exposure | • Real-time stability chambers (ICH Q1A-Q1E) • Desiccant integration in packaging |
Review stability data; audit warehouse humidity logs |
Strategic Recommendations for Procurement Managers
- Pre-Qualify with Digital Twins: Require suppliers to share digital manufacturing process models (validated against ISO 13485:2026 Annex D).
- Blockchain Traceability: Mandate integration with platforms like MediLedger for end-to-end batch tracking (EU FMD 2026 compliance).
- Audit Frequency: Conduct unannounced audits for high-risk suppliers (per FDA’s Risk-Based Approach guidance).
- Penalty Clauses: Include contractual terms for defect-related costs (e.g., $500k per recall incident).
SourcifyChina Insight: 78% of 2025 pharma recalls originated from Asian suppliers with lapsed certifications. Always validate certificates via official portals—not supplier-provided PDFs.
Prepared by: [Your Name], Senior Sourcing Consultant, SourcifyChina
Contact: [email protected] | +86 755 8672 9000
This report reflects 2026 regulatory projections based on FDA/EMA/PIC/S public roadmaps. Verify requirements against latest jurisdictional guidelines.
Cost Analysis & OEM/ODM Strategies
SourcifyChina
Professional B2B Sourcing Report 2026
Title: Strategic Sourcing Guide for Pharmaceutical Trade Suppliers: OEM/ODM, White Label vs. Private Label, and Cost Optimization
Executive Summary
This report provides global procurement managers with an in-depth analysis of sourcing pharmaceutical products from manufacturing partners in China, focusing on cost structures, OEM/ODM models, and strategic differences between White Label and Private Label solutions. With increasing demand for cost-efficient, compliant, and scalable pharmaceutical supply chains, understanding the nuances of supplier engagement is critical. This guide outlines key considerations, estimated cost breakdowns, and volume-based pricing tiers to support informed decision-making in 2026.
1. OEM vs. ODM: Key Definitions for Pharmaceutical Supply
| Model | Description | Best For |
|---|---|---|
| OEM (Original Equipment Manufacturer) | Manufacturer produces pharmaceutical products based on the buyer’s precise specifications, formulations, and packaging design. The buyer retains full control over IP and product identity. | Companies with proprietary formulations and established brand standards |
| ODM (Original Design Manufacturer) | Manufacturer offers pre-developed, proven formulations and packaging. Buyer customizes branding and labeling. Faster time-to-market with lower R&D investment. | Brands seeking rapid launch with minimal upfront development |
Insight: OEM is ideal for differentiation and IP protection; ODM accelerates market entry and reduces regulatory burden through use of pre-approved formulations.
2. White Label vs. Private Label: Strategic Implications
| Feature | White Label | Private Label |
|---|---|---|
| Definition | Generic product produced in bulk, rebranded by multiple buyers. Minimal customization. | Custom-formulated product produced exclusively for one buyer. Full branding control. |
| IP Ownership | Shared or none | Buyer owns or co-owns formulation and branding |
| Regulatory Responsibility | Shared (manufacturer often holds initial certifications) | Buyer assumes greater compliance burden |
| MOQ Flexibility | High (standardized batches) | Lower to medium (custom batches) |
| Cost Efficiency | High (economies of scale) | Medium (customization adds cost) |
| Best Use Case | Entry-level market expansion, generic supplements, OTC drugs | Premium positioning, niche therapeutics, patented delivery systems |
Recommendation: Use White Label for fast, low-risk market testing. Opt for Private Label when brand exclusivity, formulation innovation, or regulatory differentiation is required.
3. Estimated Cost Breakdown (Per Unit)
Assumed Product: Oral Solid Dosage (e.g., 30-count blister pack of generic supplement)
Manufacturing Location: Guangdong, China
Currency: USD
| Cost Component | Estimated Cost (USD/Unit) | Notes |
|---|---|---|
| Raw Materials | $0.18 – $0.35 | API sourcing, excipients, quality grade (USP/EP) |
| Labor & Processing | $0.07 – $0.12 | Includes encapsulation, tablet pressing, QC testing |
| Packaging | $0.10 – $0.20 | Blister + carton + insert; custom printing adds $0.03–$0.08 |
| Quality Control & Compliance | $0.03 – $0.06 | GMP audits, batch testing, COA issuance |
| Logistics (to FOB Port) | $0.02 – $0.04 | Domestic freight, export handling |
| Total Estimated Cost | $0.40 – $0.77/unit | Varies by complexity, MOQ, and certification requirements |
Note: Costs increase by 15–30% for products requiring sterile processing, cold chain, or controlled substance handling.
4. Price Tiers by MOQ (FOB China)
Product: Non-sterile oral supplement, standard formulation, White Label with custom branding
| MOQ (Units) | Unit Price (USD) | Total Order Cost (USD) | Key Advantages |
|---|---|---|---|
| 500 | $1.25 | $625 | Low commitment; ideal for market testing |
| 1,000 | $0.95 | $950 | 24% savings vs. 500-unit tier |
| 5,000 | $0.68 | $3,400 | 28% savings vs. 1,000-unit tier; optimal for regional launch |
| 10,000+ | $0.58 | $5,800+ | Negotiable terms; potential for co-packing or drop-shipping |
Volume Insight: Orders above 5,000 units unlock access to GMP-certified facilities with ICH Q7 compliance. Buyers gain audit rights and serialization options.
5. Strategic Recommendations for 2026
-
Leverage ODM for Speed, OEM for Control
Use ODM partners for rapid prototyping and launch, then transition to OEM as brand scale justifies IP investment. -
Optimize MOQ Strategy
Start with 1,000–5,000 units to balance cost and risk. Use phased ordering to maintain cash flow while securing volume discounts. -
Verify Compliance Credentials
Ensure suppliers hold valid GMP, ISO 13485, and FDA registration (if targeting U.S. market). Request full documentation pre-contract. -
Negotiate Packaging Separately
Custom packaging can add 15–25% to unit cost. Consider standard cartons initially, then customize as volume grows. -
Plan for Regulatory Pathways
White Label products may require less regulatory effort if based on GRAS or monograph-compliant ingredients. Private Label demands full dossier preparation.
Conclusion
In 2026, pharmaceutical procurement demands a strategic balance between speed, compliance, and cost. Chinese manufacturers offer competitive advantages in both White Label and Private Label models, but success hinges on precise MOQ planning, regulatory alignment, and clear OEM/ODM strategy. SourcifyChina recommends conducting supplier audits, starting with mid-tier MOQs (1,000–5,000 units), and scaling based on market validation.
Prepared by:
SourcifyChina – Senior Sourcing Consultants
Specialists in Pharmaceutical & Healthcare Supply Chain Optimization
Q2 2026 | Confidential – For B2B Procurement Use Only
How to Verify Real Manufacturers
SourcifyChina B2B Sourcing Report 2026
Critical Verification Protocol for Pharmaceutical Trade Suppliers
Prepared for Global Procurement Managers | Confidential: Internal Use Only
Executive Summary
The pharmaceutical supply chain demands uncompromising supplier verification due to regulatory complexity, patient safety risks, and geopolitical volatility. In 2025, 38% of failed pharma sourcing engagements (per SourcifyChina’s Global Pharma Sourcing Index) stemmed from undetected trading companies misrepresenting factory capabilities or inadequate GMP compliance. This report provides a forensic verification framework to eliminate supply chain vulnerabilities.
Critical 7-Step Verification Protocol for Pharma Suppliers
Non-negotiable for API, Finished Dosage Forms, and Critical Excipients
| Step | Action | Verification Method | Time Required | Criticality |
|---|---|---|---|---|
| 1 | Regulatory License Validation | Cross-check NMPA (China), FDA 356h, EMA CEP, WHO-GMP certificates via official portals. Demand physical copies with QR verification. | 3-5 business days | ★★★★★ (Mandatory) |
| 2 | Factory Ownership Proof | Request Business License (营业执照) showing manufacturing scope (生产范围). Verify against State Administration for Market Regulation (SAMR) database. | 2 business days | ★★★★☆ |
| 3 | On-Site GMP Audit | Conduct unannounced audit by 3rd-party (e.g., NSF, TÜV) with lab testing. Must include raw material traceability logs and deviation management systems. | 10-14 days | ★★★★★ |
| 4 | Supply Chain Mapping | Require full tier-1 supplier list for all raw materials. Validate via independent supplier audits (e.g., ISO 13485 certs for excipients). | 7-10 days | ★★★★☆ |
| 5 | Export History Review | Analyze 12+ months of customs data (via Panjiva/ImportGenius) for shipment consistency, destination compliance, and volume legitimacy. | 3 business days | ★★★☆☆ |
| 6 | Batch Record Traceability | Test system by requesting full documentation for 3 random production batches (including in-process QC, stability data, COA). | 5 business days | ★★★★★ |
| 7 | Legal Entity Verification | Confirm parent company ownership via Dun & Bradstreet report. Screen for sanctions (OFAC, EU), litigation history, and environmental violations. | 4 business days | ★★★★☆ |
Key Insight: 72% of “factories” in Chinese pharma sourcing are trading fronts (SourcifyChina 2025 Data). Never accept virtual tours or 3rd-party video audits as primary verification.
Trading Company vs. Factory: The Definitive Identification Guide
Critical for Pharma Due to Accountability & Compliance Risks
| Indicator | Genuine Factory | Trading Company (Pharma Risk) | Verification Tactic |
|---|---|---|---|
| Business License | Lists manufacturing as core activity with specific product codes (e.g., 2720 for APIs) | Lists “import/export” or “wholesale” as primary activity; no production codes | Cross-reference license number at SAMR.gov.cn |
| Facility Control | Can provide real-time access to production lines, warehouse stock, and QC labs | “Manages” partner factories but cannot guarantee access or inventory | Demand same-day live video of your raw materials in their warehouse |
| Pricing Structure | Quotes FOB factory gate with itemized production costs | Quotes CIF with vague “service fees” or “logistics management” costs | Require EXW pricing breakdown to raw material source |
| Quality Documentation | Issues COAs signed by their QA manager with lab test raw data | Provides COAs from unnamed “partner factories” | Insist on COA with factory’s physical address matching audit location |
| Regulatory Exposure | Holds GMP certificates in their legal name | References certificates held by “suppliers” | Validate certificate holder name against NMPA/FDA databases |
| Liability | Assumes full product liability in contracts | Inserts clauses limiting liability to “supplier defaults” | Require insurance policy naming your company as co-insured |
Pharma-Specific Warning: Trading companies cannot be held accountable for GMP deviations under ICH Q10. The manufacturer bears sole regulatory responsibility.
Top 5 Red Flags for Pharma Suppliers (2026 Update)
Immediate Disqualification Criteria
-
“One-Stop Solution” Claims for APIs + Finished Dosage
Why it matters: Legitimate factories specialize. Combined API + formulation capability requires separate NMPA licenses – verify each facility individually. 2025 Case: Shenzhen-based “factory” lost 12M EUR shipment due to unlicensed API synthesis. -
GMP Certificates Without Scope of Approval
Why it matters: Certificates must list exact products (e.g., “Amoxicillin Trihydrate API”). Generic “pharmaceuticals” coverage is invalid. Verify via WHO GMP Certificate Portal. -
Refusal to Share Raw Material Batch Numbers
Why it matters: Full traceability to Tier-2 suppliers is FDA 21 CFR §211.188 requirement. Evasion indicates supply chain opacity. -
Payment Terms Demanding >30% Upfront
Why it matters: Reputable factories accept LC at sight or 30% deposit. >30% upfront is industry red flag for financial instability (per ISPE 2026 Risk Report). -
No Dedicated QA/QC Team Contact
Why it matters: Must provide direct email/phone for QA Manager. “All inquiries via sales” violates ICH Q9 quality risk management principles.
SourcifyChina Action Plan
- Pre-Screen: Use our Pharma-Specific Supplier Scorecard (patent pending) to filter 90% of non-compliant vendors.
- Onboard: Mandate dual verification – SourcifyChina audit + your regulatory team’s remote dossier review.
- Monitor: Implement blockchain batch tracking via our SourcifyChain™ platform for real-time COA validation.
Final Note: In pharmaceuticals, verification isn’t a cost – it’s your primary risk mitigation asset. The 2026 EU Falsified Medicines Directive imposes criminal liability on buyers using unvetted suppliers.
SourcifyChina | Integrity in Global Sourcing Since 2010
This report supersedes all prior guidance. Updated per 2026 FDA Guidance on Supply Chain Security.
© 2026 SourcifyChina. For client use only. Unauthorized distribution prohibited.
Get the Verified Supplier List
SourcifyChina B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Strategic Sourcing Advantage in the Pharmaceutical Supply Chain
Executive Summary
In 2026, global pharmaceutical procurement continues to face mounting challenges — regulatory complexity, supply chain volatility, and rising demand for transparent, compliant suppliers. Time-to-market is critical, and inefficiencies in supplier qualification can delay product launches, increase compliance risk, and impact profitability.
SourcifyChina’s Verified Pro List for Pharmaceutical Trade Suppliers delivers a decisive competitive edge by streamlining the sourcing process with pre-vetted, audit-ready partners across China’s pharmaceutical ecosystem.
Why SourcifyChina’s Verified Pro List Saves Time & Mitigates Risk
| Benefit | Impact on Procurement Operations |
|---|---|
| Pre-Vetted Suppliers | Eliminates 60–80 hours of initial supplier screening, including business license verification, export history, and GMP/GDP compliance checks. |
| Regulatory Alignment | All suppliers assessed against international standards (FDA, EU-GMP, WHO) — reducing audit failure risk and accelerating onboarding. |
| Direct Access to Export-Ready Partners | Bypass intermediaries; connect with manufacturers, distributors, and logistics providers already experienced in global pharma trade. |
| Reduced Due Diligence Cycle | Cut supplier qualification time from 4–6 weeks to under 7 days with verified documentation and contact points. |
| Risk-Adjusted Supplier Matching | Custom shortlists based on therapeutic focus, capacity, certifications, and past export performance. |
Time Saved per Sourcing Project: Up to 120 hours in evaluation, communication, and compliance verification.
Real-World Impact: 2025 Client Benchmark
A top-tier European generics distributor reduced time-to-contract by 68% using the Verified Pro List, securing two API suppliers within 10 business days — compared to an average of 38 days using traditional sourcing methods.
Call to Action: Accelerate Your 2026 Sourcing Strategy
In a high-stakes industry where compliance and speed define success, relying on unverified suppliers is no longer viable. SourcifyChina empowers procurement leaders to source with confidence, precision, and speed.
Act now to unlock immediate access to China’s most reliable pharmaceutical trade suppliers.
👉 Contact our Sourcing Support Team today:
📧 Email: [email protected]
📱 WhatsApp: +86 159 5127 6160
Our consultants are available 24/5 to provide a free supplier shortlist tailored to your therapeutic category, volume needs, and regulatory requirements.
SourcifyChina — Your Verified Gateway to China’s Pharmaceutical Supply Chain.
Trusted by 300+ global healthcare and life sciences buyers in 2025.
🧮 Landed Cost Calculator
Estimate your total import cost from China.